RGC
NASDAQ
HK
Regencell Bioscience Holdings Limited - Ordinary Shares
$30.80
▼ $-2.92
(-8.66%)
Vol 329K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$10.4B
ROE
-54.8%
D/E
0.00
Beta
2.25
52W
$0–$84
Price Chart
Fundamentals Trend
| Metric | 2024-12-31 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -54.8% | -54.8% | -54.8% | -54.8% | -54.8% | -54.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | — | 42.68 | 42.68 | 42.68 | 42.68 | 42.68 |
Key Ratios
ROA (TTM)
-51.4%
P/B
5.1
EPS (TTM)
$-0.01
52W High
$83.60
52W Low
$0.09
$0.09
52-Week Range
$83.60
How does RGC compare to Pharmaceuticals peers?
Peer group: Large-cap Pharmaceuticals ($10B+) · 7 companies
RGC valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(18.2)
vs Peers
vs Industry
Overvalued
P/S ratio
—
▼
0%
below
peers
(3.2)
vs Peers
vs Industry
Overvalued
P/B ratio
5.1
▲
155%
above
peers
(2.0)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
In line
RGC profitability vs Pharmaceuticals peers
ROE
-54.8%
▼
572%
below
peers
(11.6%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(18.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(72.3%)
vs Peers
vs Industry
Top tier
ROA
-51.4%
▼
1335%
below
peers
(4.2%)
vs Peers
vs Industry
Weak
RGC financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(71.1)
vs Peers
vs Industry
Low debt
Current ratio
42.7
▲
2487%
above
peers
(1.7)
vs Peers
vs Industry
Strong liquidity
Beta
2.3
▲
162%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
RGC fundamentals radar
RGC
Peer median
Industry
RGC profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio